Results 141 to 150 of about 15,943 (150)

Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results

Gut, 2015
Tim Wyant, Marcela F Pasetti
exaly  

Vedolizumab

Reactions Weekly, 2023
openaire   +2 more sources

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European Gastroenterology Journal, 2019
Luisa Guidi, Daniela Pugliese, Lorenzo Bertani   +2 more
exaly  

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

Gastroenterology, 2019
Séverine Vermeire, Frank Hoentjen, Denis Franchimont   +2 more
exaly  

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology, 2019
Joseph Meserve, Satimai Aniwan, Preeti Shashi   +2 more
exaly  

Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence

World Journal of Gastroenterology, 2018
Maria Lia Scribano
exaly  

Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

Nature Medicine
Yi-Bin Chen, Robert Zeiser, takanori teshima   +2 more
exaly  

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

Scandinavian Journal of Gastroenterology, 2017
Carl Eriksson, Jan Marsal, Daniel Bergemalm   +2 more
exaly  

Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease

Inflammatory Bowel Diseases, 2016
exaly  

Vedolizumab

Österreichische Apothekerzeitung, 2014
openaire   +1 more source